These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 4281036)

  • 1. [Action of anti-plasmin in activation of the fibrinolysis system and its clinical management].
    Tabara C; Hitano E; Mizuno Y; Kazama M; Abe H
    Rinsho Byori; 1974 Oct; 22(10 Suppl):105. PubMed ID: 4281036
    [No Abstract]   [Full Text] [Related]  

  • 2. [Kinetics of fibrin lysis by plasmin: inhibition by fibrin degradation products].
    Zhitkova IuV; Aĭsina RB; Varfolomeev SD
    Bioorg Khim; 1996 Dec; 22(12):911-5. PubMed ID: 9054342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fibrinolysis activities and factor XIII in the neonatal period. 1. Fibrinolysis activity and fibrin degradation products in the neonatal period].
    Yamada Z
    Nihon Shonika Gakkai Zasshi; 1971 Apr; 75(4):294-6. PubMed ID: 4252802
    [No Abstract]   [Full Text] [Related]  

  • 4. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
    Doolittle RF; Pandi L
    Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of plasmin from cadaveric plasma on fibrinogen and fibrin].
    Levin GIa
    Prikl Biokhim Mikrobiol; 1974; 10(5):688-90. PubMed ID: 4282509
    [No Abstract]   [Full Text] [Related]  

  • 7. [Influence of antiplasmin on fibrinolysis and fibrinogenolysis].
    Bratus' GM; Byshevskiĭ ASh
    Ukr Biokhim Zh; 1971; 43(2):178-82. PubMed ID: 4254692
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasmin potency estimates: influence of the substrate used in assay.
    Philo RD; Gaffney PJ
    Thromb Haemost; 1981 Apr; 45(2):107-9. PubMed ID: 6454987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reactions of alpha 2 plasmin inhibitor to plasmin and fibrin; its significance in fibrinolysis inhibition and hemostasis].
    Ichinose A; Sakata Y; Aoki N
    Rinsho Byori; 1982 Jun; Suppl 50():178-88. PubMed ID: 6215510
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of fibrinogen degradation products on plasmin activity.
    Myśliwiec M; Arnesen H; Godal HC
    Thromb Diath Haemorrh; 1973 Jun; 29(3):592-7. PubMed ID: 4271546
    [No Abstract]   [Full Text] [Related]  

  • 12. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
    Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnostic significance of proteolytic breakdown products of fibrinogen and fibrin].
    Heene DL; Genth K
    Internist (Berl); 1984 Feb; 25(2):93-101. PubMed ID: 6231262
    [No Abstract]   [Full Text] [Related]  

  • 14. [A new quick and sensitive method for analysis of fibrin metabolism products in serum--theoretic and practical meaning].
    Gormsen J
    Nord Med; 1970 Jul; 84(31):999. PubMed ID: 4247659
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hydrolytic properties of plasmin 1 and 2 and miniplasmin].
    Kastrikina TF; Taran LD; Kudinov SA
    Dokl Akad Nauk SSSR; 1984; 278(1):240-2. PubMed ID: 6237895
    [No Abstract]   [Full Text] [Related]  

  • 16. Fibrinolysis inhibitors.
    Davis GL
    Clin Lab Sci; 1997; 10(4):212-8. PubMed ID: 10169620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen assay by means of the lysis time method.
    Berg W; Korsan-Bengtsen K; Ygge J
    Thromb Diath Haemorrh; 1965 Sep; 14(1-2):127-44. PubMed ID: 16955971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the interaction of recombinant apolipoprotein(a) with modified fibrinogen surfaces and fibrin clots.
    Sangrar W; Koschinsky ML
    Biochem Cell Biol; 2000; 78(4):519-25. PubMed ID: 11012092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.